ASH 2022 Conference Coverage
Playback speed
10 seconds
ASH 2022 NX-2127-001, a First-in-Human Trial of NX-2127, a BTK-Targeted Protein Degrader, in Patients With R/R CLL and B-Cell Malignancies
By
ASH 2022 Conference Coverage
FEATURING
Alexey Danilov
By
ASH 2022 Conference Coverage
FEATURING
Alexey Danilov
29 views
January 11, 2023
Login to view comments.
Click here to Login
Leukemia